Subscribe
31 October 2025NewsAmericasJohn Cox at Barnes & Thornburg

Is Hatch-Waxman litigation for orphan drugs working?

Rising patent litigation over rare disease treatments highlights the success of the Hatch-Waxman and Orphan Drug Acts, says John Cox at Barnes & Thornburg.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025   In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
Former pharma GC brings in-house perspective to McGuireWoods
12 September 2025   After four years as associate general counsel at a pharmaceutical company, the partner returns to private practice with experience across patents, trademarks, copyright and trade secret litigation.
Americas
Killing the golden goose of US drug innovation (Part I): Follow the money
10 September 2025   In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.


Editor's picks

Squires: ‘Inherited patent backlog was an absolute dumpster fire’
Americas
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
1 November 2025

Editor's picks

Americas
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
1 November 2025
Americas
LSPN panel unpacks critical IP risks in deal-making
23 October 2025
Americas
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
23 October 2025
Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025
Americas
Top pharma, biotech, and medtech experts gather at LSPN Fall
21 October 2025
Big Pharma
Moderna TM counsel: Commoditising work using AI is a ‘moral obligation’
16 October 2025

More features

US generics company wins patent battle over Merck Serono’s blockbuster MS drug
Novartis counsel warns: ‘Don’t let AI develop without our input’
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
Delegates descend upon Washington, DC for AIPLA Annual Meeting
Novo Nordisk counters rival with $9bn bid for obesity drug developer
‘We're being attacked from all sides’: Thermo Fisher Scientific counsel
China trademarks rankings reveal new entries, hidden gems and big brands
Edwards defends key heart valve product from infringement threat